Odyssey Study Links TNFR2 to Regulatory T Cells
Odyssey Therapeutics reports research in The Journal of Immunology on how TNFR2 activation shapes tissue-associated regulatory T cells.
Updated on Nov. 10, 2026 in Diseases

Odyssey Therapeutics published a paper titled 'TNFR2 agonism increases tissue and effector Treg cells' in The Journal of Immunology, which selected it as a 'Cutting Edge' article. The research was conducted with investigators at the University Medical Center Mainz and used single-cell analyses to examine how TNFR2 activation influences regulatory T cells.
Why it matters
The findings suggest TNFR2 agonism may expand tissue-homing regulatory T cells that suppress inflammation, a mechanism relevant to autoimmune conditions. Results so far come from mouse models and in vitro human cell studies.
In mice, a single dose of TNFR2 agonism raised PD-1+BATF+ Tregs among lung Tregs from 22% to 66%, based on animal experiments. Whether these effects carry over to human patients with inflammatory or autoimmune disease remains untested in the reported work.
The players
Odyssey Therapeutics
Odyssey Therapeutics is a biotechnology company that develops drug candidates, including the OD-003 TNFR2 agonist program referenced in the research.
The Journal of Immunology
The Journal of Immunology is a peer-reviewed scientific journal published by the American Association of Immunologists that covers immune system research.
The details
Researchers found that TNFR2 agonism increased tissue-associated Treg populations and reduced disease severity in mouse models of autoimmune inflammation. Experiments with human Tregs showed the approach promoted genes tied to tissue homing and suppressive function, and treated cells produced less IFN-γ when challenged with inflammatory signals.
Timeline
November 10, 2026: Odyssey announces publication of the TNFR2 research paper
First quarter of 2027: OD-003 expected to complete IND-enabling studies
Health Landscape
Regulatory T cell research has long centered on FOXP3-expressing cells that restrain immune responses, and this study extends that work toward tissue-resident Tregs. The approach is being pursued alongside broader efforts to treat autoimmune and inflammatory disease by modulating immune regulation rather than suppressing the immune system broadly.
Because this work is preclinical, it does not change current treatment options for patients with asthma or autoimmune disease. Any future therapy would still require IND clearance and clinical trials before it could be prescribed.
The takeaway
Immune-regulation research like this is at an early, animal-and-cell-based stage, so readers should watch for clinical trial announcements before drawing conclusions about patient benefit.
What happens next
Odyssey expects OD-003 to complete IND-enabling studies in the first quarter of 2027, a milestone that would precede any human testing.
Further reading
For more on immune-system research tied to inflammatory conditions, explore our Asthma coverage.
Source note: This article includes information reported by The Manila times.






